MET and hepatocellular carcinoma: Notably, targeted agents that inhibit angiogenesis factors while simultaneously inhibiting other key proangiogenic factors in HCC, such as fibroblast growth factor receptor (FGFR) and MET signaling, have provided insight into the underlying pathogenesis of HCC tumors (see reviews in [5]).